ASCO GU Symposium 2024
Stay up-to-date with the latest coverage of the 2024 ASCO Genitourinary Cancers Symposium.
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
The impact of squamous and other histologies on outcomes with EV are dissected.
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Dr. Tawagi provides her thoughts on treatment selection and sequencing for mUC, especially after progression on EV/pembro.
CheckMate 9ER, 67T and KEYNOTE-564 are discussed.
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Dr. Barragán-Carrillo explains the potential benefits of camu camu in reducing tumor size.
Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab.
Dr. Grivas describes the advancements in the discussion around avelumab maintenance at this year's meeting.
Dr. Brian Rini discusses KEYNOTE-564 long-term survival data and LITESPARK-005 PROs.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC.
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
While IV nivolumab has improved patient outcomes, there is a need for different administration options to improve efficiency.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
Patients with MIBC who are ineligible for cisplatin-based chemotherapy have no current standard of care options.
While belzutifan offers beneficial PFS and ORR rates, it also offers longer TTD and better PRO results versus everolimus.
New research presented at ASCO GU 2024 by Mehul Gupta, MD, described TFS rates after multiple first-line therapies.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Dr. Grünwald details the CLEAR study and a subgroup analysis on the efficacy of lenvatinib/pembrolizumab for aRCC.
Dr. Gupta details some of her latest research and describes the importance of multiple new initiatives in bladder cancer.
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Dr. Eggener describes the Stockholm3 test and reasons for validating it in an ethnically-diverse population.
Drs. Barata and Wallis highlight the efficacy of pem/len and how this IO/TKI approach compares to other strategies for aRCC.
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Improved outcomes in patients with previously untreated la/mUC after EV/pembro, even in poor prognosis patient subgroups.
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Investigators used mixture cure models to estimate patients' underlying cure fraction after radical resection.
HRQoL was maintained in the niraparib plus AAP arm, and patients experienced minimal side effect bother from treatment.
Dr. Moul details his research involving African American patients and those with high BMI and their response to ADT.
The enzalutamide group experienced a significant deterioration in mean fatigue changes when compared with the AA group.
Dr. Moul offered his insights on how prostate cancer MRI and PSMA PET compare in terms of utility and sensitivity.
Drs. Hoffman and Wallis discuss the HRQoL from FORMULA-509 trial, showing no difference in hormonal function and fatigue.
Researchers investigated the combination's effect on fatigue, cognitive impairment, and sexual function.
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Researchers noted significant differences in prostate cancer-specific survival and overall survival.
A retrospective study of patients with accRCC offers understandings of the role of tivozanib in the current RCC landscape.
The combination previously demonstrated improved progression-free survival, overall survival, and objective response rate.
Advertisement
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
Advertisement
